Fractional Flow Reserve Derived From CT Related Treatment
The Impact Of Revascularization Related By Blood Fractional Flow Reserve Calculated By Coronary Artery CTA On Prognosis
1 other identifier
observational
1,000
1 country
1
Brief Summary
This study is a retrospective, single-center study.This experiment aims to explore the influence of CT-FFR as a relevant for revascularization on the prognosis of patients with coronary heart disease, assessing concurrent on different basis the difference of prognosis of patients with revascularization was analyzed, and the significance of revascularization related by CT-FFR was analyzed.This study is a retrospective study. The treatment strategies of all patients are based on the results of CAG,including coronary revascularization.After calculating the CT-FFR value, the above doctors will formulate treatment strategies based on the results and formulate treatment strategies retrospectively.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 29, 2022
CompletedFirst Submitted
Initial submission to the registry
March 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 6, 2022
CompletedFirst Posted
Study publicly available on registry
April 8, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 29, 2022
CompletedApril 8, 2022
March 1, 2022
8 days
March 31, 2022
March 31, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause death or Myocardial infarction
Cardiovascular, non-cardiovascular and undetermined death or Target vessel related and non-target vessel related MI
1 year
Secondary Outcomes (6)
Heart failure
1 year,2 years
Non-target vessel revascularization
1 year,2 years
Cardiac death
1 year,2 years
Target vessel revascularization
1 year,2 years
Myocardial infarction
1 year,2 years
- +1 more secondary outcomes
Study Arms (2)
1.CT-FFR Related Group
Coronary diseased artery CTFFR\>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI
Coronary Angiography Related Group
Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR\>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.
Eligibility Criteria
Diagnosed or suspected coronary heart disease patients with typical symptoms or objective evidence of ischemia such as ECG, exercise treadmill, coronary CTA or CAG
You may qualify if:
- ①Diagnosed or suspected coronary heart disease patients during the diagnosis and treatment process
- From December 2017 to December 2020, coronary CTA and coronary artery CTA were performed simultaneously in Huazhong Fuwai Hospital.
- Patients with CAG (coronary CTA before coronary angiography after CAG, no more than 28 days apart).
- ③Age 18 to 75 years old.
You may not qualify if:
- ① The presence of severe artifact, dislocation or calcification in coronary CTA images affects FFRCT measurement. ② Contraindications to antiplatelet drugs
- Patients with acute myocardial infarction within 6 months④ PCI or CABG or heart transplantation and other operations that may affect the outcome ⑤ Severe heart failure⑥ Pregnant patients⑦ Combined tumor patients⑧ Life expectancy \< 2 years⑨ Have a history of other serious heart disease⑩ Contraindications for CAG⑪ Not suitable to participate in this researcher due to other reasons
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, 450000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 31, 2022
First Posted
April 8, 2022
Study Start
March 29, 2022
Primary Completion
April 6, 2022
Study Completion
April 29, 2022
Last Updated
April 8, 2022
Record last verified: 2022-03